ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AVTX vs PRTA // FORWARD P/E MULTIPLE

Avalo Therapeutics Inc. (NASDAQ) VS. Prothena Corporation plc (NASDAQ) • 15-METRIC TALLY: AVTX 1 — PRTA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTX VS. PRTA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AVTX PRTA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.90% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% -65.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.66 0.20 +0.46 AVTX /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 24.4 48.3 -23.90 PRTA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $384.5M $434.8M -$50.3M PRTA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AVTX REV PRTA REV AVTX GROSS % PRTA GROSS % AVTX FCF PRTA FCF
FY 2025 $59.0K $9.7M — — -$51.5M -$163.6M
FY 2024 $441.0K $135.2M — — -$49.1M -$150.1M
FY 2023 $1.9M $91.4M — — -$30.7M -$133.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTX // BETA —
PRTA // BETA —